Anthrax lethal toxin inhibits growth of and vascular endothelial growth factor release from endothelial cells expressing the human herpes virus 8 viral G protein-coupled receptor

Clinical Cancer Research

Volumn 13, Issue 19, 2007, Pages 5926-5934

  Depeille, Philippe ^a,c   Young, John J ^a   Boguslawski, Elissa A ^a   Berghuis, Bree D ^a   Kort, Eric J ^a   Resau, James H ^a   Frankel, Arthur E ^b   Duesbery, Nicholas S ^a  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

^b SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX TOXIN; G PROTEIN COUPLED RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACILLUS ANTHRACIS; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN HERPESVIRUS 8; IMMUNOHISTOCHEMISTRY; KAPOSI SARCOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

ANIMALS; ANTIGENS, BACTERIAL; ANTIGENS, CD31; BACTERIAL TOXINS; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOTHELIAL CELLS; MICE; MICROCIRCULATION; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; NIH 3T3 CELLS; RECEPTORS, CHEMOKINE; SARCOMA, KAPOSI; SIGNAL TRANSDUCTION; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 35348886139     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0732     Document Type: Article

References (41)

1. Collier RJ, Young JA. Anthrax toxin. Annu Rev Cell Dev Biol 2003;19:45-70.
2. Duesbery NS, Webb CP, Leppla SH, et al. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 1998;280:734-7.
3. Vitale G, Bernardi L, Napolitani G, Mock M, Montecucco C. Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor. Biochem J 2000;352:739-45.
4. Duesbery NS, Resau J, Webb CP, et al. Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways. Proc Natl Acad Sci U S A 2001;98:4089-94.
5. Koo HM, VanBrocklin M, McWilliams MJ, Leppla SH, Duesbery NS, Woude GF. Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase. Proc Natl Acad Sci U S A 2002;99:3052-7.
6. Abi-Habib RJ, Urieto JO, Liu S, Leppla SH, Duesbery NS, Frankel AE. BRAF status and mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin. Mol Cancer Ther 2005;4:1303-10.
7. Abi-Habib RJ, Singh R, Leppla SH, et al. Systemic anthrax lethal toxin therapy produces regressions of subcutaneous human melanoma tumors in athymic nude mice. Clin Cancer Res 2006;12:7437-43.
8. Nanda A, Carson-Walter EB, Seaman S, et al. TEM8 interacts with the cleaved C5 domain of collagen α3(VI). Cancer Res 2004;64:817-20.
9. Depeille PE, Ding Y, Bromberg-White JL, Duesbery NS. MKK signaling and vascularization. Oncogene 2007;26:1290-6.
10. Boshoff C, Chang Y. Kaposi's sarcoma-associated herpesvirus: a new DNA tumor virus. Annu Rev Med 2001;52:453-70.
11. Dal Maso L, Serraino D, Franceschi S. Epidemiology of HIV-associated malignancies. Cancer Treat Res 2001;104:1-18.
12. Montaner S, Sodhi A, Molinolo A, et al. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell 2003;3:23-36.
13. Flore O. Kaposi's sarcoma. Lancet 2004;364:740-1.
14. Browning PJ, Sechler JM, Kaplan M, et al. Identification and culture of Kaposi's sarcoma-like spindle cells from the peripheral blood of human immunodeficiency virus-1-infected individuals and normal controls. Blood 1994;84:2711-20.
15. Samaniego F, Markham PD, Gallo RC, Ensoli B. Inflammatory cytokines induce AIDS-Kaposi's sarcoma-derived spindle cells to produce and release basic fibroblast growth factor and enhance Kaposi's sarcoma-like lesion formation in nude mice. J Immunol 1995;154:3582-92.
16. Samaniego F, Markham PD, Gendelman R, Gallo RC, Ensoli B. Inflammatory cytokines induce endothelial cells to produce and release basic fibroblast growth factor and to promote Kaposi's sarcoma-like lesions in nude mice. J Immunol 1997;158:1887-94.
17. Samaniego F, Markham PD, Gendelman R, et al. Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development. Am J Pathol 1998;152:1433-43.
18. Sodhi A, Montaner S, Patel V, et al. The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1α. Cancer Res 2000;60:4873-80.
19. Bais C, Santomasso B, Coso O, et al. G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 1998;391:86-9.
20. Montaner S, Sodhi A, Servitja JM, et al. The small GTPase Rac1 links the Kaposi sarcoma-associated herpesvirus vGPCR to cytokine secretion and paracrine neoplasia. Blood 2004;104:2903-11.
21. Montaner S, Sodhi A, Ramsdell AK, et al. The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor as a therapeutic target for the treatment of Kaposi's sarcoma. Cancer Res 2006;66:168-74.
22. Park S, Leppla SH. Optimized production and purification of Bacillus anthracis lethal factor. Protein Expr Purif 2000;18:293-302.
23. Ridler T, Calvard S. Picture thresholding using an iterative selection method. IEEE Trans Man Cybern 1978;6:629-32.
24. Seul M, O'Gorman L, Sammon MJ. Practical algorithms for image analysis: description, examples, and code. Cambridge (New York): Cambridge University Press; 2000.
25. Chopra AP, Boone SA, Liang X, Duesbery NS. Anthrax lethal factor proteolysis and inactivation of MAPK kinase. J Biol Chem 2003;278:9402-6.
26. Bardwell AJ, Abdollahi M, Bardwell L. Anthrax lethal factor-cleavage products of MAPK (mitogen-activated protein kinase) kinases exhibit reduced binding to their cognate MAPKs. Biochem J 2004;378:569-77.
27. Friedlander AM. Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process. J Biol Chem 1986;261:7123-6.
28. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000;351:95-105.
29. Mody N, Leitch J, Armstrong C, Dixon J, Cohen P. Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway. FEBS Lett 2001;502:21-4.
30. McMullen ME, Bryant PW, Glembotski CC, Vincent PA, Pumiglia KM. Activation of p38 has opposing effects on the proliferation and migration of endothelial cells. J Biol Chem 2005;280:20995-1003.
31. Akula SM, Ford PW, Whitman AG, et al. B-Raf-dependent expression of vascular endothelial growth factor-A in Kaposi sarcoma-associated herpesvirus-infected human B cells. Blood 2005;105:4516-22.
32. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 1995;270:27489-94.
33. Ye FC, Blackbourn DJ, Mengel M, et al. Kaposi's sarcoma-associated herpesvirus promotes angiogenesis by inducing angiopoietin-2 expression via AP-1 and Ets1. J Virol 2007;81:3980-91.
34. Connolly DT, Heuvelman DM, Nelson R, et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989;84:1470-8.
35. Koch AE, Polverini PJ, Kunkel SL, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992;258:1798-801.
36. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-4.
37. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284:1994-8.
38. Pittman PR, Norris SL, Barrera Oro JG, Bedwell D, Cannon TL, McKee KT, Jr. Patterns of antibody response in humans to the anthrax vaccine adsorbed (AVA) primary (six-dose) series. Vaccine 2006;24:3654-60.
39. Little SF, Ivins BE, Webster WM, Norris SL, Andrews GP. Effect of aluminum hydroxide adjuvant and formaldehyde in the formulation of rPA anthrax vaccine. Vaccine 2007;25:2771-7.
40. Nye SH, Wittenburg AL, Evans DL, O'Connor JA, Roman RJ, Jacob HJ. Rat survival to anthrax lethal toxin is likely controlled by a single gene. Pharmacogenomics J 2007;2007:1-7.
41. Ray LB, Sturgill TW. Rapid stimulation by insulin of a serine/threonine kinase in 3T3-L1 adipocytes that phosphorylates microtubule-associated protein 2 in vitro. Proc Natl Acad Sci U S A 1987;84:1502-6.